2024 was a record year for obesity trials and 2025 is already poised to take over

There are over 300 glucagon-like peptide-1 receptor (GLP-1R) drugs in an active stage of development as the astounding success of Novo Nordisk’s GLP-1R obesity drug, Wegovy, has ignited a surge in innovator drug obesity trials. Companies are hoping to disrupt the space and loosen the stronghold that Novo Nordisk and Eli Lily, whose obesity drugs accounted for 99% of the $37.2bn GLP-1R sales in 2023, have on the market.